Whole-Exome Sequencing for Congenital Hyperinsulinism
Yes, trio whole-exome sequencing should be performed for an infant with congenital hyperinsulinism, as it can detect pathogenic variants in over 30 causative genes and directly informs critical management decisions including diazoxide responsiveness, need for 18F-DOPA PET/CT imaging, and surgical planning.
Why Genetic Testing is Essential
Establishing the genetic etiology in congenital hyperinsulinism is critical for determining whether the infant has focal versus diffuse pancreatic disease, particularly in diazoxide-unresponsive cases where this distinction determines surgical approach 1. The genetic diagnosis also predicts medication responsiveness and guides long-term surveillance strategies 1.
Genetic Heterogeneity Requires Comprehensive Testing
Congenital hyperinsulinism demonstrates substantial genetic heterogeneity with:
- Over 30 disease-associated genes identified involving ion channels (ABCC8, KCNJ11), metabolic enzymes (GLUD1, GCK, HK1, HADH), transcription factors (HNF4A, HNF1A, FOXA2), and membrane transport proteins (SLC16A1) 2, 1
- KATP channel genes (ABCC8 and KCNJ11) are most commonly mutated in severe persistent disease 2
- Mutations can include single nucleotide variants, large deletions/duplications, and methylation defects 2
Trio WES is the Optimal Testing Strategy
Trio sequencing (infant plus both parents) is superior to singleton testing because:
- It enables detection of de novo mutations and determination of inheritance patterns 3
- Parental segregation analysis helps classify variant pathogenicity 4
- It identifies compound heterozygous mutations that may be missed without parental context
- Whole-exome sequencing detects both point mutations AND large deletions in a single test 3
A 2018 study demonstrated that WES successfully identified 11 of 11 known mutations in MODY and CHI patients, including large deletions, when appropriate capture technology was used 3. More recent evidence confirms WES can achieve genetic diagnosis within 10 days when performed rapidly 5.
Clinical Impact on Management
The genetic diagnosis directly influences:
Medication decisions:
- Predicts diazoxide responsiveness (ABCC8/KCNJ11 mutations typically unresponsive) 1, 6
- Identifies atypical causes like INSR mutations that require stopping diazoxide and implementing low glycemic-index diet 6
- Detects syndromic forms requiring additional surveillance (e.g., KCNE1 mutations requiring cardiac monitoring for long QT syndrome) 7
Surgical planning:
- Determines candidacy for 18F-DOPA PET/CT imaging to identify focal lesions 1
- Guides extent of pancreatectomy (focal vs. subtotal) 4
Genetic counseling:
- Establishes recurrence risk for future pregnancies
- Enables cascade screening of family members (particularly important for autosomal dominant forms) 6
Important Caveats
- No single sequencing technology detects all genetic variants - comprehensive screening may require multiple investigations 2
- Capture technology selection matters significantly - the Nextera Rapid Capture Exome Kit demonstrated superior performance compared to Nimblegen in detecting CHI mutations 3
- Variants of uncertain significance are common and may require functional RNA analysis for interpretation 5
- Approximately 50% of cases may remain without molecular diagnosis even after comprehensive testing 4
Consent Considerations
While the infant cannot provide informed consent, fully informed parental consent must be obtained before testing 8. Parents should understand that:
- Testing may not find an answer immediately
- Results may reveal unexpected information unrelated to hyperinsulinism
- Some findings may only become clinically relevant in adulthood
- Reanalysis may be needed as scientific knowledge advances 8
The genetic diagnosis transforms congenital hyperinsulinism from a phenotype-based disorder into a genetically-informed clinical entity, enabling precision medicine approaches that improve outcomes and reduce unnecessary interventions 1.